The US Spinal Cord Stimulation market reached new heights in Q417/FY17, driven by new products, expanding indications, and a growing demand for non-narcotic alternatives for treating chronic intractable pain.SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 US Spinal Cord Stimulation Market Recap and Financial Dashboard.
Among the many topics covered in the Q417/FY17 Spinal Cord Stimulation Market Recap are:
- Annual Opioid Rx Trends
- 2017 Market Shares
- Competitive Surprises
- Nevro: Slow and Steady Gains
- Boston Scientific: Regaining Momentum
- Medtronic: Intellis Leads Turnaround
The US SCS market saw phenomenal growth in 2017, reaching revenues of ...
*This article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.